At the AD/PD 2026, Roche showcased new five-year data from the Phase II PASADENA trial (NCT03100149) involving prasinezumab.

Biomarker data presented at AD/PD 2026 from the Phase III APOLLOE4 trial showed that , valiltramiprosate treatment in the MCI ...

Roche will no longer progress emugrobart to late-stage trials in FSHD and SMA, as the drug has failed to demonstrate ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

The START Center for Cancer Research (START) has partnered with Trialing, aimed at increasing oncology clinical trial access ...

YolTech Therapeutics has received clearance from the US FDA to begin a Phase II/III clinical study of its in vivo ...

Shionogi has enrolled the first patients in its global Phase II clinical trial, Esprit, assessing the investigational drug ...

Eli Lilly’s investigational first-in-class GIP, glucagon-like peptide 1 receptor (GLP-1R) and glucagon triple hormone ...

EnteroBiotix has completed enrolment in the Phase IIa MAST trial of EBX-102-02 in patients undergoing allo-HSCT for ...

Mirum Pharmaceuticals has completed enrolment in the Phase III EXPAND study assessing Livmarli in rare cholestatic liver ...

Aspen Neuroscience’s autologous, personalised stem cell therapy is set for a pivotal trial after it showed improved "ON" and ...

New recommendations for tuberculosis (TB) diagnostic techniques from the WHO may mark a major step towards accessible testing ...